United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
435.84
+16.63 (3.97%)
Oct 1, 2025, 3:30 PM EDT - Market open
United Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover United Therapeutics stock have a consensus rating of "Buy" and an average price target of $459.6, which forecasts a 5.45% increase in the stock price over the next year. The lowest target is $302 and the highest is $600.
Price Target: $459.6 (+5.45%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Buy | 2 | 2 | 3 | 3 | 3 | 5 |
Hold | 4 | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 12 | 13 | 13 | 13 | 15 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
UBS | UBS | Strong Buy Maintains $560 → $580 | Strong Buy | Maintains | $560 → $580 | +33.08% | Sep 29, 2025 |
RBC Capital | RBC Capital | Buy Initiates $569 | Buy | Initiates | $569 | +30.55% | Sep 26, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $405 → $525 | Buy | Maintains | $405 → $525 | +20.46% | Sep 10, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $510 → $575 | Buy | Maintains | $510 → $575 | +31.93% | Sep 5, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $400 → $500 | Strong Buy | Maintains | $400 → $500 | +14.72% | Sep 5, 2025 |
Financial Forecast
Revenue This Year
3.27B
from 2.88B
Increased by 13.71%
Revenue Next Year
3.45B
from 3.27B
Increased by 5.38%
EPS This Year
28.07
from 24.64
Increased by 13.91%
EPS Next Year
29.10
from 28.07
Increased by 3.67%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.4B | 3.7B | |||
Avg | 3.3B | 3.4B | |||
Low | 3.1B | 3.0B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 19.1% | 13.3% | |||
Avg | 13.7% | 5.4% | |||
Low | 6.5% | -8.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 34.20 | 33.14 | |||
Avg | 28.07 | 29.10 | |||
Low | 24.75 | 23.03 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 38.8% | 18.1% | |||
Avg | 13.9% | 3.7% | |||
Low | 0.4% | -17.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.